Cargando…

HIV-1 reverse transcriptase complex with DNA and nevirapine reveals nonnucleoside inhibition mechanism

Combinations of nucleoside and nonnucleoside inhibitors (NNRTIs) of HIV-1 reverse transcriptase (RT) are widely used in anti-AIDS therapies. Five NNRTIs including nevirapine are clinical drugs; however, the molecular mechanism of inhibition by NNRTIs is not clear. We determined the crystal structure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Das, Kalyan, Martinez, Sergio E., Bauman, Joseph D., Arnold, Eddy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359132/ https://www.ncbi.nlm.nih.gov/pubmed/22266819 http://dx.doi.org/10.1038/nsmb.2223

Ejemplares similares

Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage
por: Das, Kalyan, et al.
Publicado: (2014)

Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol
por: Figueiredo, Anna, et al.
Publicado: (2006)

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors
por: Jiang, Xiangyi, et al.
Publicado: (2023)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors
por: Sluis-Cremer, Nicolas
Publicado: (2014)

Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring
por: Paneth, Agata, et al.
Publicado: (2019)

N(1),N(3)-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase
por: Novikov, Mikhail S., et al.
Publicado: (2013)

Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase
por: Kuroda, Daniel G., et al.
Publicado: (2013)

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
por: Ankrom, Wendy, et al.
Publicado: (2021)

What do docking and QSAR tell us about the design of HIV-1 reverse transcriptase nonnucleoside inhibitors?
por: Paneth, Agata, et al.
Publicado: (2017)

Investigation of the solvent-dependent photolysis of a nonnucleoside reverse-transcriptase inhibitor, antiviral agent efavirenz
por: Jordaan, Maryam A, et al.
Publicado: (2017)

Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design
por: Bauman, Joseph D., et al.
Publicado: (2008)

Integrative structural biology studies of HIV-1 reverse transcriptase binding to a high-affinity DNA aptamer
por: Tuske, Steve, et al.
Publicado: (2020)

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
por: Cha, Yu-Jung, et al.
Publicado: (2014)

Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs
por: Boyer, Paul L., et al.
Publicado: (2019)

Dyslipidemia among HIV-infected Patients with Tuberculosis Taking Once-daily Nonnucleoside Reverse-Transcriptase Inhibitor–Based Antiretroviral Therapy in India
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2011)

Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors
por: Liu, Genyan, et al.
Publicado: (2018)

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants
por: Johnson, Barry C, et al.
Publicado: (2012)

Response to Therapy in Antiretroviral Therapy–Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor–Associated Transmitted Drug Resistance
por: Clutter, Dana S., et al.
Publicado: (2016)

N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance
por: Yap, Soo-Huey, et al.
Publicado: (2007)

Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
por: Karamchand, Sumanth, et al.
Publicado: (2016)

Crystal Structure of a Retroviral Polyprotein: Prototype Foamy Virus Protease-Reverse Transcriptase (PR-RT)
por: Harrison, Jerry Joe E. K., et al.
Publicado: (2021)

Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors
por: Singh, Kamalendra, et al.
Publicado: (2014)

Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Nonnucleoside Reverse Transcriptase Inhibitor
por: Gillespie, Gillian, et al.
Publicado: (2021)

Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies
por: Singh, Abhimanyu K., et al.
Publicado: (2022)

Sliding of HIV-1 reverse transcriptase over DNA creates a transient P pocket – targeting P-pocket by fragment screening
por: Singh, Abhimanyu K., et al.
Publicado: (2021)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
por: Mastan, SK, et al.
Publicado: (2009)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Me-Better Drug Design Based on Nevirapine and Mechanism of Molecular Interactions with Y188C Mutant HIV-1 Reverse Transcriptase
por: Wang, Yan, et al.
Publicado: (2022)

Architecture of an HIV-1 reverse transcriptase initiation complex
por: Larsen, Kevin P., et al.
Publicado: (2018)

Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach
por: Mansouri, Mahta, et al.
Publicado: (2023)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
por: Wong, Alexander, et al.
Publicado: (2019)

Impact of Integrase Inhibition Compared With Nonnucleoside Inhibition on HIV Reservoirs in Lymphoid Tissues
por: Rothenberger, Meghan, et al.
Publicado: (2019)

Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity
por: Lake, Jordan E., et al.
Publicado: (2015)

Natural presence of the V179D and K103R/V179D mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors in HIV-1 CRF65_cpx strains
por: Liu, Yongjian, et al.
Publicado: (2020)

Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)
por: Brown, Jennifer A., et al.
Publicado: (2021)

Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals
por: Mbuagbaw, Lawrence, et al.
Publicado: (2016)

Structure of HIV-1 RT/dsRNA initiation complex prior to nucleotide incorporation
por: Das, Kalyan, et al.
Publicado: (2019)

Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor–Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis
por: Bertagnolio, Silvia, et al.
Publicado: (2020)

Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir Resistance
por: Das, Kalyan, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_o5c3l7u8cg5gdb1jdpfc4tulrh